ciglitazone has been researched along with Leukemia, Basophilic, Acute in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Leukemia, Basophilic, Acute: A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lenman, A | 1 |
| Fowler, CJ | 1 |
1 other study available for ciglitazone and Leukemia, Basophilic, Acute
| Article | Year |
|---|---|
Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents; Brain; Brain Neoplasms; Cannabinoid Receptor Mod | 2007 |